Member Info for bignose58

Anyway, heartening to see a few days of increases with no let up. (finished 16% up, although 16% of about nothing is still about nothing....).

Long may it continue ....news this or next week perhaps ??? ........ LOL.

All True Dougie, although this time its different................ I can feel it in me water ..... LOL

All a bit immaterial unless a T/O as they buy the company and the listing. If no T/O, investors ignore the listing price since its all about sentiment. We were at 0.06 at one point, so listing value never entered the equation.

Mind you, do the recent changes in law and how the world sees it (non democratic society and US as well as other countries companies moving out) reduce this. How does a HK listing valuation compare to that of Shanghai, as an example. If HK is indeed absorbed by the mainland, how long will there be a need for the HKSE ?

HK listing was meant to be worth 40mill USD (verified by JM), so still a long way to go to that figure.

gif = gift the t just vanished :-O

Certainly is. it still need to go up 100% to reach the sp at the time of JG's loan, share placing, gif, whatever at 0.25HKD (I think he got them for 0.225HKD to JG)... lol

I'm afraid I'm a little skeptical about the Rx-to-OTC switch since they didn't perform any market consumer research before the initial launch and my understanding is they have/are done/doing nothing pre-change approval. So what makes them think it will make a difference. I could be wrong (and hopefully I am), but the price will more than likely be again reduced and the product will take a long time to get even a modicum of interest. Will any form of advertising help given the amount of national paper articles that appeared to be shown during the launches .... thoughts ?

I would guess no advertising can be shown until the approval is official. But still appears to be no market research into who will buy if changed to OTC.

And that was something I didnt know. Regent (I assume its Regent given there are no RNS's and postings appear to be for the TO duration) having a BB here on LSE for the durtaion of the RPG-PLE T/O.... And it still exists 4 years on !!!

"Regnon Ord Regulatory News (0O8O)"

Now how on earth did they manage that (if it is Regent related) ? even LIFE (another failed JM driven investment) has disappeared and that was entitled to a BB.... A funny old world.

Exactly...there are NOEXCUSES why this shouldnt be a lot higher now........... ;-)

Thanks for that Heimdal. Maybe he should read this ====>

http://www.regentpac.com/ICMServlet/download/13-1953-3176/EAnnt-VSA(FirmOfferforPlethora)-15Dec2015.pdf

Not forgetting the 10:1 consolidation that happened a couple of months later. and the exchange rate of 11.7271 at the time (currently at 10.37, so we are 13% better off at this moment in time).

Thanks for that.

Singapore is currently one of the safest places on the planet. Although 56k cases only 2.3k are community cases (cumulative since Feb). All the other cases are for foreign workers (out of about 500k Indians and Chinese) kept in Dormitories like animals, hence the high numbers from too close contact.

Not too happy if there is to be some reverse TO unless it happens next year and the sp is back in the 0.4 region since any dilution now will just carp on all the longterm holders who are currently well under water. And if it’s anything like the DBC debacle, we certainly are stuffed. The board are not qualified to make any decisions on Pharma or anything else given their track record. Although they may have somelimited ability to choose a stick of rock from the local sweet shop. ;-)

If there is US interest, I'm sure it has nothing to do with the EU, but more to do with the Phase II/III and license agreement/s. Remember, RPG are now making ref to "either before or during phase III" with respect to an agreement being signed, which they have only recently started referring to. I wouldn't be surprised if the ref to 20 to 24 months now instead of the 6 to 10 months, which the company has regularly referred to in the last 6 years, is to deliberately try and create a sellers market to allow others to buy in. (who knows what tricks JG and JM may be up to to get what they want. I mean, historically they only have had their own interests at heart.) Why now when we are much closer than before is JG trying to convince shareholders the NDA to FDA timeline is longer insinuating that there is a problem !!!

Anything over 10 months is a problem, it sates as much on the FDA website...... >>>
https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review#:~:text=Directions%20for%20use-,FDA%20Review,whether%20to%20approve%20the%20drug.

Nope, I think something is up....... in a good way. AIMHO .....of course.....lol

Good morning The.Italian,

I too was a little apprehensive at first, however. Given that in this instance the buying has been over a much longer period of time makes me think that there is more to it than the usual P'n'D. Also, given Heimdal's ref to US buying could indicate there is more likely a leak across the pond. Although I hope this leak doesn't empty the pond but instead overfills it.

Something does appear to be afoot which I am sure we will know about soon enough.......just my opinion of course.

Hopefully it will spike higher and last longer than what happened in Nov 2016 which ended up just being puff n bluster leading to nothing.

Heimdal......

Someones finally let you out to play. How are things with you in HK it certainly must be difficult times given the C-19 and now China syndrome. Anyhow, hope you are riding the storm.

Certainly appears that some news has been leaked given this is about the 5th time in the last few weeks that there has been consistent large buys. It certainly would indicate (more so, given your ref to the US broker interest). Certainly not the pump and dumps as previous.

Hopefully if a license agreement is forthcoming in the next month or two, they will also pay for the phase III trials. I guess the fact that Jim is currently lending the company money rather than the company seeing a placing, points towards that. (Maybe we are really lucky and a licensee buys the license for the whole of the US North and South).

Certainly seems like they are keeping a very tight trading range. Could this be to allow a licensee to buy a **** load so they get some money back once the agreement is out there or even, dare I suggest, a lesser offer can be made for remaining shares if a TO ???

Stay safe and make sure you buy that open, one way return ticket to wherever your roots are.....you may need it sooner than later.

Yup.
My thoughts exactly. Something positive to think about instead of filling my mind with the doom n gloom.... lol

The.Italian,
Nothing wrong in your figures. It was my error........ I Inadvertently based it on the 0.1 figure I’d referred to earlier.... :-)

That last trade at 8 mins after closing and which dragged the sp down 2% was for only 10k shares and was a Non-AMS (not automated). Some real dodgy bookkeeping going on to manipulate the price down. It will be interesting to see how tomorrow starts.

At close only 2% up, although it was up 18% during the day. Volume at close was 15 odd mill buys to 6 odd mill sells. Certainly not such a large sp increase for the volume. Seems to be following the same procedure as all the other recent high volume days and could indicate there is some jiggery pokery going on, but for what purpose ?

Continued....... extracted from the 2014 annual report. (I include the below lest long term investors forget exactly what BS we were being advised and for those that may not even know what BS was already out there in cyberspace.

To proceed in the manufacture of a 20 dose product in compliance with
the existing EMA approval. The decision to dual source the product was taken to minimize the risk of any delay in the supply of a compliant product for the purposes of launching PSD502™ in the EU for preserving the sunset date and commencing the clinical trials for the completion of the New Drug Application with the USA Food and Drug Administration (FDA) (Meaning they intended to go down the rout of using the 20 dose can for the FDA approval process at teh beginning of 2015 ???)

Discussions and negotiations are currently taking place with:

(i) A global pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for certain countries in LATAM, Asia Pacific (including Australia) and South Africa. The parties have entered into non-binding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.

(ii) A multinational pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East region. The parties have entered into non-binding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.

And even though they wrote "The Company hopes to be in a position to make further announcements during the course of 2015 relating to its out licensing activities." shareholders have never been advised as to why all these heads of terms agreements fell apart (Note 1.China was never even considered until after June 2016, 2. These are in addition of the already in place agreement with Recordati and 3. Being after there was an issue with the 6 dose can and a solution was being worked on with variable sizes being tried resulting in the 12 dose can).

Read it it and enjoy.....lol